Gillian Lowe MA, MB BChir, MRCP, FRCPath, PhD, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, shares some updates on the management of immune thrombocytopenia (ITP). Dr Lowe first highlights the importance of new Phase II studies in ITP, such as the FLIGHT trial (NCT03156452) and another trial looking at upfront romiplostim alongside dexamethasone for the treatment of ITP patients in the UK. Additionally, Dr Lowe discusses ADA2 deficiency as a potential cause of stroke in young patients and concludes by sharing some insights into the future of ITP, including novel agents and immunosuppressants, and the importance of giving patients a choice when choosing medications. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.